Analysis Estimates Brand-Name Drug Costs Will Continue to Rise

Brand-name prescription drug costs are likely to continue to rise, with the biggest increases seen in insulins and tumor necrosis factor (TNF) inhibitors, according to a new study published in JAMA Network Open.
 
Over a 6-year period, the analysis mapped out drugs cost patterns for the 49 top-selling brand-name medications in the United States based on pharmacy claims data from a health insurance database. Top selling medications were identified as drugs that exceeded $500 million in US sales or $1 billion in worldwide sales.
 
From January 2012 through December 2017, the researchers found a median 76% increase in costs, or a 9.6% annual compounded increase. Of the 36 drugs that have been available since 2012, 78% have seen an increase in insurer and out-of-pocket costs by more than 50% and 44%, respectively, according to the study. In total, 35% of the drugs more than doubled in costs. The authors noted that insulin products and TNF inhibitors specifically demonstrated highly correlated price increases and made up some of the largest price hikes in the industry. 
 
In many cases, cost increases for most of the drugs were observed 1 to 2 times per year, according to the study. Only 1 drug, hepatitis C medication ledipasvir/sofosbuvir (Harvoni), decreased in cost over time; however, the decrease was no more than 1% annually.
 
According to the study, the researchers estimated that costs for popular brand-name drugs would double every 7 to 8 years.
 
Although 17 of the study drugs had FDA-approved therapeutic equivalents, this did not appear to affect cost changes. The authors noted that this suggests prices of brand-name drugs are not largely affected by generic drugs or biosimilar products that enter the market. Additionally, competition between brand-name competitors, such as adalimumab (Humira) and etanercept (Enbrel), demonstrated some of the largest cost increases in the industry over the study period.
 
“Implementation of the price transparency legislation passed in October 2018 may guide patients to seek lower-priced alternatives to brand-name drugs when available, which may ultimately lead to different price trends in the future compared with the trends we observed,” the authors wrote. “However, this likelihood is unknown.”
 
The authors concluded that reasonable drug costs should be balanced with incentives in the pharmaceutical industry to produce innovative therapies.
 
“Innovative solutions, such as the Institute for Clinical and Economic Review’s value-based price benchmark, have the potential to find appropriate price points for patients while rewarding drug manufacturers that produce transformative products,” they wrote.
 
Reference
 
Topol EJ, Wineinger NE, Zhang Y, et al. Trends in prices of popular brand-name prescription drugs in the United States. JAMA Network Open. 2019. Doi: 10.1001/jamanetworkopen.2019.4791
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

As more novel therapies emerge from the pipeline and enter the market, it is crucial for pharmacists to monitor new drug approvals that could be lifechanging for their patients.
A ‘fail-first’ policy by the Centers for Medicare and Medicaid Services could be a nightmare for patients with cancer, according to the Community Oncology Alliance.
Researchers seek to investigate how to broaden the potential of cediranib with and olaparib to treat multiple cancer types.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$